BiomX, Inc. Quarterly report pursuant to Section 13 or 15(d)

Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2021

	September 30, 2021
	Level 1		Level 2		Level 3		Fair Value
Assets:
Cash equivalents:
Money market funds		30,007		-		-		30,007
Foreign exchange contracts receivable		-		20		-		20
		30,007		20		-		30,027
Liabilities:
Contingent consideration (*)		-		-		180		180
		-		-		180		180

	December 31, 2020
	Level 1		Level 2		Level 3		Fair Value
Assets:
Cash equivalents:
Money market funds		30,000		-		-		30,000
Foreign exchange contracts receivable		-		90		-		90
		30,000		90		-		30,090
Liabilities:
Contingent consideration (*)		-		-		83		83
		-		-		83		83

(*) Changes in contingent consideration for the nine months ended on September 30, 2021 and 2020 resulted from revaluation.